| Compound Information | SONAR Target prediction |
| Name: | OUABAIN |
| Unique Identifier: | SPE01500676 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 540.303 g/mol |
| X log p: | -0.419 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 44.76 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 12 |
| Rotatable Bond Count: | 4 |
| Canonical Smiles: | CC1OC(OC2CC(O)C3(CO)C4C(O)CC5(C)C(CCC5(O)C4CCC3(O)C2)C2COC(=O)C=2)C(O) C(O)C1O |
| Class: | sterol glycoside |
| Source: | Acokanthera and Strophanthus spp |
| Reference: | Ann Rev Biochem 15: 155 (1946); Helv Chim Acta 42: 1418 (1959); 45: 1244 (1962); 50: 2299 (1967) |
| Therapeutics: | antiarrhythmic, cardiotonic, hypertensive, Na/K ATPase inhibitor |
| Generic_name: | Ouabain |
| Chemical_iupac_name: | 4-[1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-(3,4,5-trihydroxy-6-methyl- tetrahydropyran-2-yl)oxy-2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17-hexadecahydro-1H-cy clopenta[a]phenanthren-17-yl]-5H-furan-2-one |
| Drug_type: | Approved Drug |
| Kegg_compound_id: | C01443 |
| Drugbank_id: | APRD00135 |
| Melting_point: | 200 oC |
| H2o_solubility: | 1.03E+004 mg/L |
| Logp: | -2.038 |
| Cas_registry_number: | 630-60-4 |
| Drug_category: | Cardiotonic Agents |
| Indication: | For the treatment of atrial fibrillation and flutter and heart failure |
| Pharmacology: | Ouabain, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. |
| Mechanism_of_action: | Ouabain inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Ouabain also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential. |
| Organisms_affected: | Humans and other mammals |
| Found: 205 nonactive as graph: single | with analogs | 1 2 3 4 5 6 7 8 9 10 Next >> [205] |
| Species: | 4932 |
| Condition: | BCK1 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.8970±0.0218496 |
| Normalized OD Score: sc h | 1.0294±0.00422315 |
| Z-Score: | 0.5981±0.0719508 |
| p-Value: | 0.550266 |
| Z-Factor: | -2.32184 |
| Fitness Defect: | 0.5974 |
| Bioactivity Statement: | Nonactive |
| ps |
| DBLink | Rows returned: 72 | 1 2 3 4 5 6 7 8 9 10 Next >> |
| 4605 | 4-[1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-(3,4,5-trihydroxy-6-methyl-oxan-2-yl)oxy-2,3,4, 6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one |
| 10506 | 4-[(3S,5R,10S,13R,14S,17S)-14-hydroxy-10,13-dimethyl-3-[(2R,5R)-3,4,5-trihydroxy-6-methyl-oxan-2-yl]oxy- 1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one |
| 11013 | 4-[(3S,5R,10S,11R,13R,14S,17S)-11,14-dihydroxy-10,13-dimethyl-3-[(2R,5R)-3,4,5-trihydroxy-6-methyl-oxan- 2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one |
| 12420 | 4-[(1R,3S,5S,10R,11R,13R,14S,17S)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2S,3R,4R,5S,6S )-3,4,5-trihydroxy-6-methyl-oxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phena nthren-17-yl]-5H-furan-2-one |
| 18620 | 4-[(3S,5S,10R,13R,14S,17S)-5,14-dihydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,5R)-3,4,5-trihydroxy-6-met hyl-oxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-5H-furan-2 -one |
| 19880 | 4-[(3S,5S,10R,13R,14S,17S)-5,14-dihydroxy-10,13-dimethyl-3-[(2S,5R)-3,4,5-trihydroxy-6-methyl-oxan-2-yl] oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one |
| internal high similarity DBLink | Rows returned: 10 | 1 2 Next >> |
| SPE01500986 | 0.9038 |
| SPE00100698 | 0.9038 |
| SPE01501205 | 0.9135 |
| SPE01503994 | 0.9223 |
| SPE01501113 | 0.9314 |
| SPE01500247 | 0.9592 |
| active | Cluster 3148 | Additional Members: 5 | Rows returned: 0 |
Service provided by the
Mike Tyers Laboratory